Best cellular rejuvenation therapies

Fisetin is a natural compound with senolytic properties that has been shown to reduce senescence markers in human studies. Its safety profile and preliminary results position it as a promising senolytic, both in pharmaceutical research and in the supplement market.

This experimental gene therapy, developed by Life Biosciences and co-founded by David Sinclair of Harvard Medical School, represents a significant breakthrough. It is the first cellular rejuvenation therapy using epigenetic reprogramming to receive FDA authorization for human clinical trials, marking a milestone in the fight against aging.

This senolytic combination is one of the most researched in humans, with pioneering studies published in 2019. It has been shown to reduce senescent cells and improve certain aging-related conditions, such as idiopathic pulmonary fibrosis.

Identified in 2025, this HSP90 protein inhibitor represents a breakthrough in the development of senolytics. It reduces the burden of senescent cells and inflammatory interleukin levels in animal models, with favorable tolerability and lower toxicity.

This advanced approach uses modified T-cells to selectively target and eliminate senescent cells. It is one of the most innovative precision senolytic therapies in development, with the potential to offer highly specific elimination of aged cells.

MSCs are one of the most widely used types of stem cells in anti-aging therapies due to their versatility and safety profile. They are valued for their anti-inflammatory and immunomodulatory properties, and their ability to regenerate damaged tissues and improve skin health.

iPSCs represent the future of personalized therapies, allowing for the creation of specific cells for tissue and organ regeneration without the ethical concerns of embryonic stem cells. They are under advanced research in 2026 for their versatility and potential.

These stem cells, obtained from tissues such as the umbilical cord or placenta, have great regenerative potential and a favorable immunological profile. They are a promising source for regenerative medicine and rejuvenation, with growing interest in their application.

This combination of stem cells with biomedical scaffolds is a dominant trend in regenerative medicine for 2026. It improves cartilage and bone tissue regeneration, offering more durable therapeutic responses and superior structural and functional integration.

The use of exosomes, vesicles secreted by cells, is on the rise in 2026 as an adjuvant or alternative therapy to stem cells. They offer lower immunological risk, a better safety profile, and greater pharmacological stability, making them promising for various applications.

This approach allows for genetic editing of stem cells to correct monogenic defects and enhance regenerative effects. It is showing promising results in hematological, muscular, and metabolic diseases, opening the door to highly specific treatments for the genetic causes of aging.